Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 1968457)

1.

Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.

Gleason RP, Schneider LS.

J Clin Psychiatry. 1990 Mar;51(3):115-8.

PMID:
1968457
2.
3.

A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease.

Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS.

Am J Geriatr Psychiatry. 2001 Fall;9(4):400-5.

PMID:
11739066
4.

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.

Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C.

Am J Psychiatry. 1998 Jan;155(1):54-61.

PMID:
9433339
5.

Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease.

Risse SC, Lampe TH, Cubberley L.

J Clin Psychiatry. 1987 May;48(5):207-8.

PMID:
2883174
6.

A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.

Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, Cooper TB, Pelton GH, Mayeux R.

Am J Psychiatry. 1998 Nov;155(11):1512-20.

PMID:
9812111
7.

Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.

Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L; Alzheimer's Disease Cooperative Study; Valproate Nursing Home Study Group.

Am J Geriatr Psychiatry. 2005 Nov;13(11):942-9.

PMID:
16286437
8.

Behavioral symptoms in Alzheimer's disease: phenomenology and treatment.

Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A.

J Clin Psychiatry. 1987 May;48 Suppl:9-15.

PMID:
3553166
9.

Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.

Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW.

Int J Geriatr Psychiatry. 2005 Nov;20(11):1020-7.

PMID:
16250069
10.

Carbamazepine treatment of agitation associated with dementia.

Leibovici A, Tariot PN.

J Geriatr Psychiatry Neurol. 1988 Apr-Jun;1(2):110-2.

PMID:
3252879
11.

No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.

Weiner MF, Tractenberg RE, Sano M, Logsdon R, Teri L, Galasko D, Gamst A, Thomas R, Thal LJ.

J Geriatr Psychiatry Neurol. 2002 Summer;15(2):95-8.

PMID:
12083600
12.

Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia.

Tariot PN, Jakimovich LJ, Erb R, Cox C, Lanning B, Irvine C, Podgorski CA.

J Clin Psychiatry. 1999 Oct;60(10):684-9.

PMID:
10549685
13.

A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F.

J Clin Psychiatry. 2003 Feb;64(2):134-43.

PMID:
12633121
14.
15.

Low-dose divalproex in agitated patients with Alzheimer's disease.

Dolder C, McKinsey J.

J Psychiatr Pract. 2010 Jan;16(1):63-7. doi: 10.1097/01.pra.0000367781.26507.86.

PMID:
20098234
16.

[A preliminary study of low dosage zuclopenthixol depot in Alzheimer's disease].

Robles A, Rodríguez Navarrete FJ, Taboada O, Docasar L, Páramo M, Noya M.

Rev Neurol. 1996 Mar;24(127):273-5. Spanish.

PMID:
8742387
17.

Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease.

Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST.

Arch Neurol. 1999 Oct;56(10):1266-72.

PMID:
10520944
18.

Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms.

Negrón AE, Reichman WE.

Int Psychogeriatr. 2000 Dec;12(4):527-36.

PMID:
11263718
19.

Beneficial effects of perospirone on aggressive behavior associated with dementia.

Sato S, Mizukami K, Moro K, Tanaka Y, Asada T.

Psychiatry Clin Neurosci. 2006 Feb;60(1):106-9.

PMID:
16472367
20.

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.

Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanagh S, Schneider LS.

Curr Alzheimer Res. 2007 Jul;4(3):325-35.

PMID:
17627490
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk